Clinical Trial

A Study of SPY002-091 in Healthy Volunteers

Active, Not Recruiting Phase 1
View on ClinicalTrials.gov →
Summary
This is a Phase 1, randomized, double-blind, placebo-controlled, single- dose, first in human safety, tolerability, and pharmacokinetic study of SPY002-091 in healthy participants.
Protocol Amendment History 3 amendments
This ClinicalTrials.gov record has been amended 3 times since 2024-11-01; most recent amendment 2026-06-10.
Status change: Recruiting → Active, Not Recruiting 2026-06-10
Status change: Not Yet Recruiting → Recruiting 2024-11-04
Trial Details
NCT Number NCT06672718
Lead Sponsor Spyre Therapeutics, Inc.
Collaborators: Altasciences Company Inc.
Conditions Healthy
Enrollment 50 participants
Start Date 2024-11-26
Primary Completion 2026-08-19 (estimated)
Study Completion 2026-08-19 (estimated)
Updated on ClinicalTrials.gov 2026-06-12